This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
